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A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of
phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay
(ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to
the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1%) of 29 patients with
a BI of 4.0 or above and in 15 (68.2%) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients
with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I
in serum declined rapidly by about 90% 1 month after the start of multidrug therapy. This study showed clearly
that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated
leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in the
assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemo-
therapy.
Despite the rapid reduction of registered leprosy cases in the
last decade, leprosy is still a major public health problem in
several countries (16). The finding of no substantial decrease in
the new-case detection rate (684,998 new cases reported in
1997 ([16]) during the same period undermines the successful
multidrug therapy (MDT) programs directed by the World
Health Organization (WHO). Despite the WHO efforts to
eliminate leprosy by the year 2000, areas of hyperendemic
infection remain in many countries. In such areas, sensitive and
specific laboratory diagnostic tests will be of great value in
detecting leprosy patients at the early stages.
There have been tremendous efforts to develop sensitive and
specific serodiagnostic tests, and these have been reported in
the literature. Among the antigens evaluated for immunoas-
says, phenolic glycolipid I (PGL-I) is still the only Mycobacte-
rium leprae-specific antigen (8), and it has been widely used for
the serodiagnosis of leprosy. The presence of the M. leprae-
specific antigen(s) in clinical samples would be indicative of
current M. leprae infection. PGL-I was thus the target antigen
of choice because of its specificity to M. leprae and its abun-
dance. As well, there have been several studies of the detection
of PGL-I in various clinical specimens such as serum (1, 4, 12,
17), urine (4, 9, 10, 13), nasal washes (13), and biopsy speci-
mens (14) for diagnosis and determination of the prognosis
following chemotherapy for leprosy.
In general, the PGL-I antigen is detectable in clinical spec-
imens mostly from multibacillary (MB) patients, mainly due to
the limited sensitivity of the current detection methods and to
the rapid decline of its level in sera soon after starting chemo-
therapy against leprosy (1, 10, 12). However, it has not been
well established what proportion of MB patients are positive
for the PGL-I antigen in their sera. The present study was
therefore designed to compare the bacterial indices with
PGL-I detection in sera from untreated leprosy patients. In
addition, the PGL-I antigen level was measured semiquantita-
tively in sera obtained serially from leprosy patients after start-
ing MDT. The results were then compared with bacterial in-
dices (BI) and immunoglobulin M (IgM) antibodies to the
antigen to determine which parameter was the better indicator
to monitor the effectiveness of chemotherapy against leprosy.
MATERIALS AND METHODS
Study patients and serum samples. A total of 100 untreated patients were
recruited prospectively among the leprosy patients who presented at the Skin
Clinics of the Leonard Wood Memorial Center for Leprosy Research in Cebu
City, Philippines. All patients were classified based on clinical findings, his-
topathological examination, and BI on the Ridley and Jopling scale (11). Of 100
patients enrolled for the study, 28 patients were classified as lepromatous (LL),
32 as borderline lepromatous (BL), 27 as borderline tuberculoid (BT), 12 as
tuberculoid (TT), and one as indeterminate; 89 patients were bacteriologi-
cally positive (MB), and 11 were acid-fast bacillus negative (paucibacillary).
Serum samples were obtained from the study patients before starting treatment
and serially at regular intervals of 1, 2, 4, 6, 9 and 12 months after starting WHO
MDT.
Detection of PGL-I antigen in serum specimens. The procedure was a modi-
fication of that described previously (4), and it was faster (3, 5). To facilitate the
extraction of total lipids from serum specimens, a single 100-ml specimen was
added to a filter paper disk (0.5 in. in diameter) (Schleicher & Schuell, Inc.,
Keene, N.H.) and dried completely. The lipids were then extracted using 2 to 3
ml of CHCl3-CH3OH (2:1) solution and dried under N2. Serum lipids were
dissolved in CHCl3, applied to a Pasteur pipette packed with Florisil 60–100
mesh (Sigma Chemical Co., St. Louis, Mo.), and eluted with CHCl3 followed by
5% CH3OH in CHCl3. The lipid fraction eluted with 5% CH3OH was saved and
dried under N2 and examined for the presence of PGL-I.
The dot enzyme-linked immunosorbent assay (ELISA) described by Hawkes
et al. (7) was used with minor modification as reported previously (3, 5). The
purified lipid was dissolved in 100 ml of hexane, and a 5-ml portion was applied
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to a Tuffryn (polysulfone) membrane (HT-200; Gelman Sciences, Inc., Ann Arbor,
Mich.), as originally used by Young et al. (17). High-titer rabbit anti-PGL-I
antiserum, prepared as described previously (4), was used as the primary anti-
body, and peroxidase-conjugated goat anti-rabbit IgG (Cappel, Organon
Teknika Co., Durham, N.C.) was used as the secondary antibody. For color
development, 4-chloro-1-naphthol (Bio-Rad Laboratories, Inc., Richmond, Cal-
if.) was used and the results were read visually.
For comparison of the PGL-I antigen level in serum samples, purified lipid
from 100 ml of serum was twofold serially diluted to 1:256 in hexane, and 5 ml of
diluted lipid was applied to the Tuffryn membrane and subjected to the dot
ELISA procedures described above. The highest dilution showing evidence of
PGL-I was considered to be the titer of PGL-I in this study in order to compare
the PGL-I level between serum samples.
In each experiment, PGL-I was included at concentrations of 2.5, 1.0, 0.5, and
0.25 ng per spot as a positive control, and hexane was included as a negative
control. The detection limit was set at 0.5 to 1.0 ng of PGL-I, and any experiment
giving a higher detection limit was considered invalid and repeated.
Detection of antibodies to PGL-I. An ELISA described by Voller et al. (15)
was used with minor modification as reported previously (3, 6; however, instead
of the native glycolipid, the semisynthetic neoglycoprotein O-(3,6-di-O-methyl-b-
D-glucopyranosyl)-(134)-(2,3-di-O-methyl-a-1-rhamnopyranosyl)-(139)-oxy-
nonanoyl–bovine serum albumin (natural disaccharide-octyl-BSA [ND-O-BSA])
(2) was used. Briefly, 50 ml of diluted ND-O-BSA (20 ng of sugar/ml) in car-
bonate buffer (pH 9.6) was added to the wells of U-bottom microtiter plates
(Dynatech Laboratories, Inc., Alexandria, Va.), and incubated overnight at 37°C
in a moist chamber. The wells were then washed with phosphate-buffered saline
(PBS) solution (pH 7.4) containing 0.05% Tween 20 (PBST) and blocked by the
addition of 100 ml of PBST–0.05% BSA at 37°C for 1 h. After the wells were
emptied, 50 ml of serum diluted 1:300 in PBST–5% normal goat serum (Gibco
Laboratories, Grand Island, N.Y.) was added to the wells, which were then
incubated at 37°C for 90 min. After the wells were washed, 50 ml of affinity-
purified peroxidase-conjugated goat anti-human IgM (Behring Diagnostics, San
Diego, Calif.) diluted 1:5,000 in PBST–5% normal goat serum was added and
incubation was continued at 37°C for 1 h. After another wash, 50 ml of substrate
solution, H2O2–o-phenylenediamine, was added to the wells, which were then
incubated at room temperature for about 15 min. The reaction was stopped with
50 ml of 2.5 N H2SO4, and the absorbance was read at 490 nm.
Each test was performed in duplicate, and the mean absorbance of BSA-only
wells was subtracted from that of wells with ND-O-BSA before analysis.
RESULTS
Detection of PGL-I in untreated patients. Crude lipids were
extracted from serum samples obtained from leprosy patients
before starting chemotherapy, and the lipid fractions contain-
ing the PGL-I antigen were purified using the Florisil column.
The purified lipids were then applied to a polysulfone mem-
brane and subjected to dot ELISA. The results were read
visually, and some of the dot ELISA results are shown in Fig.
1. In general, the size and color intensity of dots varied mark-
edly from 11 (Fig. 1 dot 5E) to 21 (dot 4B) to 31 (dot 6A)
between serum samples. This thus indicated that the circulat-
ing PGL-I level in blood is markedly different between pa-
tients.
To determine the range of BI in leprosy patients whose
serum samples were PGL-I positive, the leprosy patients were
grouped based on PGL-I detection results, and the BI of lep-
rosy patients were plotted in each group. As shown in Fig. 2,
PGL-I was detectable in patients with BI as low as 2.2, al-
though the majority of PGL-I-positive patients had BI over 3.0.
On the other hand, a portion of leprosy patients with BI over
3.0 had no circulating PGL-I antigen in sera detectable by the
method employed in this study. When the prevalence of PGL-I
antigenemia was analyzed based on the average BI, the PGL-I
antigen was detectable in sera from 27 (93.1%) of 29 patients
with BI of 4.0 to 5.0, from 15 (68.2%) of 22 patients with BI of
3.0 to 3.9, and from 2 (16.7%) of 12 patients with BI of 2.0 to
2.9, respectively (Table 1). However, none of the 37 patients
with BI of less than 2.0 had circulating PGL-I antigen in their
sera. When the results were analyzed based on the clinical
spectrum of leprosy, PGL-I was detectable in 25 (89.3%) of 28
LL patients, 18 (56.3%) of 32 BL patients, and 1 (3.7%) of 27
BT patients (data not shown). None of 13 TT and 1 indeter-
minate patients had PGL-I antigenemia.
FIG. 1. Dot ELISA for the detection of the PGL-I-containing lipid
fraction from serum samples of leprosy patients. A 5-ml portion of
serum lipid dissolved in hexane was applied to each square, and the
rest of the ELISA steps were then carried out. Any visible dot was
considered PGL-I antigen positive. Note the difference in the sizes and
intensities of dots because of different quantities of PGL-I in serum.
FIG. 2. Distribution of BI of patients with or without detectable
PGL-I antigen in their serum specimens.
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Monitoring the PGL-I level after chemotherapy. A semi-
quantitative assay was used to compare PGL-I antigen levels
before and after starting chemotherapy. The purified lipid frac-
tion containing PGL-I was serially diluted twofold in hexane,
and each diluted lipid was assayed for the presence of PGL-I.
Figure 3 shows some of the results of PGL-I titer determina-
tions in sera serially obtained from a leprosy patient. The
PGL-I titer in serum obtained before treatment was 1:128, and
it decreased rapidly to 1:8 2 months after starting chemother-
apy and was barely detectable at 6 months. Likewise, eight
patients with BI of 4.5 or over were examined for their PGL-I
antigen levels weekly during the first month of chemotherapy
and after 2, 4, and 6 months. In addition, anti-PGL-I IgM
antibodies were assayed in the serum samples and the results
were compared with the PGL-I antigen level. As expected, the
mean titer of PGL-I antigen decreased rapidly soon after start-
ing chemotherapy: by about 50% within 2 weeks of chemother-
apy, by about 90% after 1 month, and by more than 95% after
2 months (Fig. 4). Six of eight patients had no PGL-I detect-
able 6 months after starting MDT. In contrast, there was no
significant decrease in mean anti-PGL-I IgM antibody levels
during the first 6 months, particularly in the patient group.
Thus, PGL-I antigen seems to be a good marker for monitor-
ing the effectiveness of chemotherapy during the early phase of
MDT.
To determine the duration of PGL-I antigenemia in patients
undergoing MDT, serum samples obtained at predetermined
intervals from leprosy patients were examined for the presence
of the PGL-I antigen. In general, within 2 to 6 months of
starting MDT, the PGL-I antigen level declined rapidly to
undetectable in serum samples from patients who had a low
(11; group I) or moderate (21; group II) level of PGL-I at the
time of diagnosis (Table 2). Only one (6.3%) of 16 patients
with a PGL-I level of 21 had the antigen detectable in this
study after 6 months of therapy. Although patients with a high
level (31; group III) of PGL-I at the time of diagnosis showed
a longer duration of PGL-I antigenemia, 14 (77.8%) of 18
patients were PGL-I antigen negative after 6 months of MDT
and only 1 patient had circulating PGL-I antigen after 12
months of MDT. In contrast, there was no substantial decrease
in BI in the majority of patients after 12 months of MDT. The
mean BI declined from 4.3 6 0.5 at the time of diagnosis to
3.4 6 0.8 after 12 months of MDT in group III. This was in
comparison to the other groups, in which the BI declined from
4.2 6 0.7 to 2.9 6 0.9 after 12 months for group II patients and
from 3.4 6 0.7 to 1.5 6 0.5 for group I patients. The results
clearly indicate that PGL-I antigen is a better indicator for
monitoring the effects of chemotherapy on leprosy.
DISCUSSION
This study showed that the majority of MB leprosy patients
with BI over 3.0 had PGL-I antigenemia and that the PGL-I
antigen disappeared from the circulation within 6 months of
starting MDT. This thus indicated that the PGL-I antigen is a
useful marker for monitoring the effect of MDT in leprosy
patients with high bacterial loads. Since PGL-I is the M. leprae-
specific antigen, the presence of the antigen in serum and other
clinical samples may indicate an active M. leprae infection in
the body. Previous studies showed that the PGL-I antigen was
detectable in serum, urine, and biopsy samples from certain
groups of leprosy patients, primarily MB patients. However, it
has not been fully evaluated what proportion of MB patients
would have PGL-I antigenemia and how long the antigen
would be present in blood after starting MDT in leprosy pa-
tients.
One of the objectives of this study was therefore to deter-
mine the proportion of patients with PGL-I antigenemia in
comparison to the average BI of leprosy patients. As expected,
PGL-I was detectable in most serum samples from untreated
leprosy patients with an average BI over 4.0. Its prevalence
declined markedly among patients with a BI of 3.0 to 4.0, and
it was hardly detectable in sera from patients with a BI less
than 3.0. These results supported reports by Roche et al. (12)
and Chanteau et al. (1), in which the majority of leprosy pa-
tients with a BI over 4.0 or LL patients had PGL-I antigenemia
before starting MDT. The presence of PGL-I in sera thus
clearly reflects the higher bacterial loads. It was also of interest
that several patients whose BI was over 3.0 had no detectable
PGL-I in sera, despite having a relatively high BI, up to 4.0 to
4.2. The patients with a BI over 4.0 had a relatively high level
of anti-PGL-I antibodies despite the absence of the antigen in
serum (data not shown), indicating production of PGL-I by M.
FIG. 3. Titer determination of PGL-I-containing lipids purified
from serum samples that were obtained serially from a leprosy patient
following chemotherapy. Rows: A, before starting chemotherapy; B, 1
week after starting chemotherapy; C, 2 weeks; D, 3 weeks; E, 1 month;
F, 2 months; G, 4 months; H, 6 months; I, 9 months.
TABLE 1. Detection of PGL-I in sera from untreated
leprosy patients
BI No. of sera assayed No. (%) of PGL-I-positive seraa
0.0–1.9 37 0 (0)
2.0–2.9 12 2 (16.7)
3.0–3.9 22 15 (68.2)
4.0–5.0 29 27 (93.1)
a Determined by dot ELISA.
140 CHO ET AL. CLIN. DIAGN. LAB. IMMUNOL.
leprae. Such an absence of PGL-I antigenemia in MB patients
with BI over 4.0 was also reported by Roche et al. (12). One
possible explanation would be previous medication with anti-
leprosy drugs despite denial by the patients at the time the
clinical history was obtained.
The other objective of this study was to closely monitor the
PGL-I level immediately after the start of MDT in leprosy
patients. When the PGL-I level in sera were measured semi-
quantitatively in serial serum samples, PGL-I declined rapidly.
Even 1 week after the start of MDT, there was an indication of
a decrease in PGL-I level, and the mean PGL-I titer was
reduced by one-half after 2 weeks of MDT in this study. Pre-
viously, it was shown that the PGL-I titer apparently declined
in serum samples obtained at least 1 or 2 months after starting
MDT (1, 4, 12, 17). The results suggested that PGL-I was
actively secreted from live M. leprae into surrounding tissues,
and as soon as the bacilli were killed by chemotherapy, the
PGL-I antigen was no longer produced and only the residual
antigens in tissues and in blood disappeared from the circula-
tion with a half-life of about 2 weeks.
The duration of PGL-I antigenemia was apparently well
correlated with the initial level of PGL-I antigen in sera, which
also reflected the bacterial loads in leprosy patients. PGL-I was
barely detectable in sera from patients after 6 months of MDT.
Only about 13% of patients who had PGL-I antigenemia be-
fore chemotherapy had PGL-I antigen in sera detectable by
the method used in this study. Chanteau et al. (1) also showed
that 3 of 10 patients had residual PGL-I in sera 6 months
after the start of MDT and that PGL-I level decreased by
97% 1 year after MDT in MB leprosy patients. Therefore,
the PGL-I level in serum or other clinical samples may be a
useful marker for monitoring the effectiveness of MDT
among MB patients, particularly during the early stage of
chemotherapy.
Interestingly, Roche et al. (12) reported that PGL-I levels
decreased very rapidly in patients infected with drug-sensitive
M. leprae but decreased slowly in patients infected with drug-
resistant bacilli or with the erythema nodosum leprosum
(ENL) reaction. In our study, however, no patients relapsed
from WHO MDT even 3 to 4 years after their release from
treatment. Therefore, it was not possible to correlate the an-
tigen clearance rate with the outcome of relapse of drug-
resistant M. leprae infection. In addition, although there were
10 ENL patients among the study patients, we did not note any
significant delay in PGL-I antigen clearance compared to those
in patients with the same BI at the time of diagnosis. The slow
clearance of PGL-I antigen in sera from ENL patients may
reflect a high BI at the beginning of treatment.
As indicated in the literature, therefore, the PGL-I antigen
detection assay can be added to the existing methods for lab-
oratory assessment of leprosy patients after starting MDT. To
date, the morphological index has been used for early assess-
ment of MDT, but it has not been reliable, mainly due to
variation in the results. BI has thus been most widely used for
monitoring the effectiveness of MDT in leprosy patients. How-
ever, at least 1 year is required to see any measurable decrease
in BI. Anti-PGL-I antibody levels also decreased following
MDT, but the reduction rate was measured at 50% after 2
years. PGL-I antigen detection thus seems to have an ad-
vantage over morphological index, BI, and anti-PGL-I anti-
body assay for monitoring the effects of chemotherapy of
leprosy.
FIG. 4. Comparison between the PGL-I antigen level and anti-PGL-I serum antibody levels following chemotherapy of lepromatous leprosy
patients. Each value represents the mean and standard deviation for eight patients.
TABLE 2. Detection of PGL-I in sera obtained serially from
leprosy patients after starting MDT
Patient
groupa
No. of PGL-I-positive patients
Before
MDT
After MDT
1 mo 2 mo 4 mo 6 mo 9 mo 12 mo
I 5 2 1 0
II 16 15 8 4 1 0
III 18 18 16 9 4 2 1
a Groups are based on the initial PGL-I level. Groups I, 11; group II, 21;
group III, 31 (by visual grading of dot ELISA results as shown in Fig. 1).
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